Skip to Content
COVID-19 Resources
Cancer Therapy Evaluation Program (CTEP)
Contact NExT
Show menu
Search this site
Last Updated: 03/28/16

John J. Wright, MD, PHD

John J. Wright, MD, PHD

Associate Branch Chief, IDB

Dr. Wright received a PhD in molecular virology from the University of Illinois Medical Center and his medical degree from Northwestern University Medical School in Chicago. He completed internship and residency training in Internal Medicine at the University of Virginia in Charlottesville. He then was a research fellow in the Metabolism Branch of the National Cancer Institute. Dr. Wright completed a medical oncology fellowship in the NCI Medicine Branch and served several years on the clinical staff at the NCI-Navy Medical Oncology Branch and the Uniformed Services University of the Health Sciences. He then joined the Investigational Drug Branch of CTEP and after several years was named an Associate Branch Chief. He oversees a portfolio of investigational agents, including signal transduction inhibitors, proteasome inhibitors, and histone deacetylase inhibitors and has an interest in nanotechnology-based cancer therapeutics. He organizes the annual NCI CTEP Early Drug Development Meeting and coordinates the selection process for the Michaele C. Christian Oncology Drug Development Award.

Contact Information:
National Cancer Institute
9609 Medical Center Dr., MSC 9739
For USPS: Bethesda, MD 20892-9739
For Express and Courier: Rockville, MD 20850
Phone: 240-276-6105
Fax: 240-276-7894

About the Branch Chief

Jeffrey A. Moscow, MD Jeffrey A. Moscow, MD, joined the Investigational Drug Branch (IDB) in 2014 after serving part time since 2012, and was appointed Branch Chief in 2018. He is a graduate of Harvard University and the Geisel School of Medicine at Dartmouth. Dr. Moscow completed his pediatric residency at the University of Texas Southwestern in Dallas and a fellowship in pediatric hematology-oncology in the Pediatric Oncology Branch, NCI. More…